A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa

doi:10.19871/j.cnki.xfcrbzz.2022.02.015

Abstract

Abstract: One 82-year-old male patient suffering from Alzheimer's disease was admitted to the hospital due to repeated pulmonary infection in the past half-year. Carbapenem-resistant Acinetobacter baumannii (CRAB）and Carbapenem-resistant Pseudomonas aeruginosa(CRPA）were cultured in the sputum so he was treated with a variety of antibiotics including tigecycline before admission. However, Pulmonary infection and sputum culture of CRAB and CRPA did not show any sign of improvement. After admission, a single-phage preparation for CRAB and a two-phage cocktail preparation for CRPA was nebulized twice daily, combined with intravenous administration of tigecycline, piperacillin-tazobactam and amikacin. Phages for CRAB lasted for 10 days and phages for CRPA lasted for 19 days in total. The treatment was well tolerated and resulted in clearance of the CRAB and reduction of CRPA. Clinical signs and chest X-ray indicated that the pulmonary infection was improved gradually.

Key words: Phage, Carbapenem-resistant Acinetobacter baumannii, Carbapenem-resistant Pseudomonas aeruginosa, Pulmonary infection, Drug-resistant bacteria

Chen Peifen, Kong Yingjun, Wen Si, Gu Xiaowen, Zhou Yang, Tan Xin, Ma Yingfei, Lu Hongzhou. A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(2): 71-75.

References

[1] 梁庄万,张群,蒋秋燕,等.重症监护室老年感染性疾病病原菌分布及耐药性分析[J/CD].新发传染病电子杂志,2021, 6(2): 96-99.
[2] WONG D,NIELSEN TS, BONOMO RA, et al.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges[J]. Clin Microbiol Rev, 2017,30(1):409-447.
[3] TACCONELLI E, CARRARA E, SAVOLDI A, et al.Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327.
[4] COHAN FM, ZANDI M, TURNER PE.Broadscale phage therapy is unlikely to select for widespread evolutionn of baterial cresistance to virus infection[J]. Virus Evol, 2020, 6(2): veaa060.
[5] YIN S, HUANG G, ZHANG Y, et al.Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii[J]. Cell Physiol Biochem, 2017, 44(6):2337-2345.
[6] WITTEBOLE X, ROOCK DE, OPAL SM.A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens[J]. Virulence, 2014, 5(1): 226-235.
[7] SHEN GH, WANG JL, WEN FS, et al.Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii[J]. PLoS One, 2012, 7(10): e46537.
[8] EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL. Rapid risk assessment: carbapenem-resistant Acinetobacter baumannii in healthcare settings-8 December 2016.[EB/OL]. http://ecdc.europa.eu/publications-data/rapidrisk-assessment-carbapenem-resistant-acinetobacter-bau-manniihealthcare.
[9] 周华,俞云松,周建英.多重耐药鲍曼不动杆菌感染治疗进展[J]. 中华内科杂志, 2015,54( 7) : 644-647.
[10] SATO Y,UNNO Y,KAWAKAMI S,et al.Virulence characteristics of Acinetobacter baumannii clinical isolates vary with the expression levels of omps[J]. J Med Microbiol, 2017,66( 2) : 203-212.
[11] SCHOOLRY RT, BISWAS B, GILL JJ, et al.Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection[J]. Antimicrob Agents Chemother, 2017, 61(10): e00954-e00917.
[12] TAN X, CHEN H, ZHANG M, et al.Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease[J]. Front Cell Infect Microbiol, 2021, 11: 631585.
[13] WU N, DAI J, GUO M, et al.Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients[J]. Emerg Microbes Infect, 2021, 10(1):612-618.
[14] 林佳冰, 高晓东, 崔扬文,等. 上海市90所医院临床病原学标本送检及耐药菌检出现状分析[J].中华医院感染学杂志, 2018, 28(8):1162-1165.
[15] KALIL AC, METERSKY ML, KLOMPAS M, et al.Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63(5):575-582.
[16] PENA C, CABOT G, GOMEZ-ZORRILLA S, et al, Spanish Network for Research in Infectious Diseases (REIPI). Influence of virulence geno-type and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections[J]. Clin Infect Dis, 2015, 60:539-548.
[17] WALKTY A, LAGACE-WIENS P, ADAM H, et al.Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015[J]. Diagn Microbiol Infect Dis, 2017, 87:60-63.
[18] SADER HS, CASTANHEIRA M, DUNCAN LR, et al.Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program[J]. Diagn Microbiol Infect Dis, 2018, 92: 69-74.
[19] US DEPARTMENT OF HEALTH, SERVICES H. Antibiotic resistance threats in the United States, 2013[EB/OL]. [2013-12-18]. https://www.michigan.gov/-/media/Project/Websites/mdhhs/Folder2/Folder92/Folder1/Folder192/AR_Key_Points_for_Partners.pdf?rev=6712581e77fa4cebad8.
[20] WORLD HEALTH ORGANIZATION.Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis[M]. Geneva: World Health Organization, 2017.
[21] JAULT P, LECLERC T, JENNES S, et al.Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial[J]. Lancet Infect Dis, 2019, 19(1): 35-45.
[22] FURR CL, LEHMAN SM, MORALES SP, et al.P084 bacteriophage treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a cystic fibrosis patient[J]. Journal of Cystic Fibrosis, 2018,17(S3): S83.
[23] MADDOCKS S, FABIJAN AP, HO J, et al.Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa[J]. Am J Respir Crit Care Med, 2019,200(9):1179-1181
[24] WRIGHT A, HAWKINS CH, ANGGARD EE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4): 349-357.
[25] 郭孝兰,李永伟.铜绿假单胞菌耐药机制与生物被膜相关性研究进展[J/CD].新发传染病电子杂志, 2017, 2(3):188-191.
[26] CHAUDHRY WN, CONCEPCION-ACEVEDO J, PARK T, et al.Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms[J]. PLoS ONE, 2017, 12: e0168615.
[27] OECHSLIN F, PICCARDI P, MANCINI S, et al.Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence[J]. J Infect Dis, 2016, 215:703-712.